A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/12 (2006.01) A61K 31/05 (2006.01) A61K 31/11 (2006.01) A61K 31/235 (2006.01)
Patent
CA 2238098
A method for the prevention and treatment of atherosclerosis and its related diseases in mammals, in which an NADPH oxidase inhibitor is administered, is provided. The NADPH oxidase inhibitor prevents the production of reactive oxygen species upon exposure of endothetial cells to atherogenic LDL levels, thus resulting in decreased endocytosis and vascular hyperpermeability. Preferred NADPH oxidase inhibitors are of formula (I). Additionally, there is provided a diagnostic method for predicting risk of a human patient to atherosclerotic-related diseases.
L'invention concerne une méthode de prévention et de traitement de l'athérosclérose et des pathologies voisines chez les mammifères, dans laquelle on administre un inhibiteur de la NADPH-oxydase. Cet inhibiteur empêche la production de formes actives de l'oxygène due à l'exposition des cellules endothéliales à des taux athérogènes de LDL-cholestérol, entraînant une diminution de l'endocytose et une hyperperméabilité vasculaire. La formule des inhibiteurs préférés de la NADPH-oxydase est la suivante (I). L'invention concerne également une méthode diagnostique permettant de déterminer, chez un patient humain, la prédisposition aux maladies liées à l'athérosclérose.
Holland James A.
Johnson David K.
Gowling Lafleur Henderson Llp
The Research Foundation Of State University Of New York
LandOfFree
Use of nadph oxidase inhibitors for the manufacture of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of nadph oxidase inhibitors for the manufacture of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nadph oxidase inhibitors for the manufacture of a... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1670227